Tenpoint’s YUVEZZI sets new benchmark in presbyopia eye drop efficacy and safety
YUVEZZI becomes the first FDA-approved dual-agent eye drop for presbyopia. Find out what this means for Tenpoint Therapeutics and the future of vision care.
Novaliq targets uveitis with EyeSol-based NOV05: Can topical tacrolimus go intraocular?
Novaliq’s NOV05 enters Phase 2 trials for anterior uveitis. Can it deliver steroid-free, topical relief for inner-eye inflammation? Find out what’s next.
Why the Nanodropper–Bedo–Viseon merger could reset the rules of personalized eyecare
Mu Medical unites Nanodropper, Bedo, and Viseon into a precision eyecare platform. Find out what this could mean for the future of AI-led ophthalmology.
FDA gives go-ahead to GenEditBio’s first genome-editing trial for TGFBI corneal dystrophy
GenEditBio Limited, a Hong Kong–headquartered clinical-stage biotechnology firm focused on in vivo genome-editing therapies, announced that the United States Food and Drug Administration has cleared its Investigational New Drug application for GEB‑101, a CRISPR-based candidate for TGFBI corneal dystrophy. This regulatory milestone authorizes the launch of the Phase 1/2 CLARITY trial in the United States, […]